Comparing Continuing Tenofovir, Emtricitabine (or Lamivudine) Plus Lopinavir and Switching to Raltegravir Plus Darunavir (SPARE)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The main objective of this clinical trial in randomizing HIV infected patients under good HIV control with tenofovir (TDF), emtricitabine (or lamivudine) plus lopinavir/ritonavir (LPV/r) into switching the regimen to raltegravir (RAL) with darunavir/ritonavir (DRV/r) or continuing the ongoing regimen to compare these two groups' estimated glomerular filtration rate (eGFR) is to investigate whether anti-HIV treatment that does not contain TDF or other reverse-transcriptase inhibitors (NTRI sparing regimen) can be protective of patients' renal functions and has the same virological efficacy in comparison with a standard treatment with TDF, or not.
| Condition | Intervention |
|---|---|
|
HIV Infections |
Drug: Switching regimen to raltegravir and darunavir/ritonavir |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Switching From Lopinavir/Ritonavir Plus Tenofovir and Emtricitabine (or Lamivudine) to Darunavir (Prezista) and Raltegravir to Evaluate Renal Function |
- eGFR improvement comparison of two arms by ITT analysis [ Time Frame: 48 weeks ] [ Designated as safety issue: Yes ]To investigate whether the estimated glomerular filtration rate (eGFR) of the intervened group with RAL+DRV/r improves by 10% or more by intention to treat (ITT) analysis at the time of 48 weeks after the start of the study, or not.
- Virological efficacy [ Time Frame: 48 weeks up to 96 weeks ] [ Designated as safety issue: Yes ]Virological efficacy of the group on DRV/r+RAL
- Renal function markers [ Time Frame: 48 weeks up to 96 weeks ] [ Designated as safety issue: Yes ]Serum creatinine, eGFR, uine beta-2 microglobulin, tubular resorption rate of phosphate, urine albumin, N-acetyl-beta-glucosaminidase, serum cystatin C, urine protein and urine glucose
- Lipids [ Time Frame: 48 weeks up to 96 weeks ] [ Designated as safety issue: Yes ]Triglycerides, HDL cholesterol, LDL cholesterol and total cholesterol
- Adverse events [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]Adverse events of each arm, symptoms and rate
- Blood plasma concentration of RAL and DRV [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]Blood plasma concentration level of raltegravir and darunavir among all consented and intervened cases at National Center for Global Health and Medicine
- Discontinuation rate [ Time Frame: 96 weeks ] [ Designated as safety issue: Yes ]Discontinuation rate of each arm, reason and timing
| Estimated Enrollment: | 54 |
| Study Start Date: | February 2011 |
| Estimated Study Completion Date: | February 2013 |
| Estimated Primary Completion Date: | February 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Raltegravir, Darunavir/r
An arm to change the regimen from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID |
Drug: Switching regimen to raltegravir and darunavir/ritonavir
An arm to change the regimen to: Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD Other Name: NRTI sparing regimen
|
|
No Intervention: Tenofovir, Emtricitabine (or 3TC), Lopinavir/r
An arm continuing on the same regimen before the randomization as Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD
|
Detailed Description:
Eligibility criteria are HIV infected outpatients or inpatients that are:
without history virological failure including protease inhibitors or raltegravir (disregarding whether the patient had a history of drug resistance or drug holiday, or not) taking LPV/r+TVD (or TDF+lamivudine) for longer than 15 weeks before the enrollment with HIV viral load less than 50 copies/ml for 15 weeks, including those with blips (one time episode of detectable level HIV viraemia which are proceeded and followed by undetectable viraemia).
20 years old or older Japanese willing to participate in the trial and able to agree to the informed consent. Main outcome measures are to investigate if the estimated glomerular filtration rate (eGFR) of the intervened group with RAL+DRV/r improves by 10% or more by intention to treat (ITT) analysis at the time of 48 weeks after the start of the trial.
Other outcome measures are:
virological efficacy of the group on DRV/r+RAL (after 48 weeks and up to 96 weeks) comparison of other renal function markers between the two arms: serum creatinine, urine beta-2 microglobulin, tubular resorption rate of phosphate, urine albumin, N-acetyl-beta-glucosaminidase, serum cystatin C, urine protein and urine glucose (after 48 weeks and up to 96 weeks) comparison of lipid markers between the two arms: triglycerides, HDL cholesterol, LDL cholesterol and total cholesterol (after 48 weeks and up to 96 weeks) discontinuation rate of each arm, reason and timing of the discontinuation or the treatment change up to 96 weeks adverse events of each arm, symptoms and rate up to 96 weeks blood plasma concentration level of RAL and DRV of all consented intervened cases at National Center for Global Health and Medicine
Eligibility| Ages Eligible for Study: | 20 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria: HIV infected outpatients or inpatients that are
- without history virological failure including protease inhibitors or raltegravir (disregarding whether the patient had a history of drug resistance or drug holiday, or not)
- taking LPV/r+TVD (or TDF+lamivudine) for longer than 15 weeks before the enrollment
- with HIV viral load less than 50 copies/ml for 15 weeks, including those with blips (one time episode of detectable level HIV viraemia which are proceeded and followed by undetectable viraemia)
- 20 years old or older
- Japanese
- willing to participate in the trial and able to agree to the informed consent
Exclusion Criteria: cases applicable to any of the following will be excluded from this trial
- HBs antigen positive within 15 weeks to the enrollment (cases confirmed as HBs antibody positive can be enrolled without HBs antigen testing)
- malabsorption or gastrointestinal symptoms that affect absorption of the drugs, or dysphagia cases
- clinical data within 15 weeks before the start of the trial and of the closest date to the enrollment that are GPT 2.5 times the highest of the normal range (grade 2) or eGFR less than 60ml/min (Cockcroft-Gault formula)
- cases with opportunistic infections requiring treatment (primary and secondary preventive prophylaxis can be administrated during the study)
- cases during pregnancy or nursing period, or with a possibility for pregnancy
- using drugs that are prohibited to combine for drug interaction with the drugs of this trial
- other cases that are decided by the patient's physician as not suitable for the trial
Contacts and Locations| Japan | |
| National Center for Global Health and Medicine | |
| Shinjuku, Tokyo, Japan, 1628655 | |
| Principal Investigator: | Shinichi Oka, MD PhD | National Center for Global Health and Medicine |
More Information
No publications provided
| Responsible Party: | National Center for Global Health and Medicine, Japan |
| ClinicalTrials.gov Identifier: | NCT01294761 History of Changes |
| Other Study ID Numbers: | FWA00005823-SPARE2011, UMIN000005116 |
| Study First Received: | February 10, 2011 |
| Last Updated: | January 16, 2012 |
| Health Authority: | Japan: Ministry of Health, Labor and Welfare |
Keywords provided by National Center for Global Health and Medicine, Japan:
|
HIV-1 AIDS Clinical Trials, Randomized |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Lamivudine Tenofovir Tenofovir disoproxil Ritonavir |
Lopinavir Darunavir Emtricitabine Reverse Transcriptase Inhibitors Nucleic Acid Synthesis Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Pharmacologic Actions Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Therapeutic Uses Anti-HIV Agents HIV Protease Inhibitors Protease Inhibitors |
ClinicalTrials.gov processed this record on May 19, 2013